



ABN 53 075 582 740

## ASX ANNOUNCEMENT

18 December 2020

---

### Lapse of Employee Share Options & Warrants

Bionomics Limited (ASX: BNO, OTCQB:BNOEF), a global, clinical stage biopharmaceutical company announced today that for the period from 7 August 2020 to 18 December 2020, 409,500 unlisted employee share options at various prices lapsed.

The total number of unlisted employee share options is 5,832,050.

In addition, 24,124,484 Warrants at an exercise price of \$0.5938 and 345,232 Warrants at an exercise price of \$0.5288 lapsed.

AUTHORISED BY AND FOR FURTHER INFORMATION PLEASE CONTACT:

Mr Jack Moschakis  
Legal Counsel & Company Secretary  
+61 8 8354 6181  
[jmoschakis@bionomics.com.au](mailto:jmoschakis@bionomics.com.au)

#### About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, is a novel, proprietary negative allosteric modulator of the alpha-7 ( $\alpha 7$ ) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

[www.bionomics.com.au](http://www.bionomics.com.au)